Galectin genes: regulation of expression. by Chiariotti, Lorenzo et al.
Glycoconjugate Journal 19, 441–449, 2004
C© 2004 Kluwer Academic Publishers. Manufactured in The Netherlands.
Galectin genes: Regulation of expression
Lorenzo Chiariotti1, Paola Salvatore2, Rodolfo Frunzio3 and Carmelo B. Bruni2
1Dipartimento di Medicina Sperimentale e Clinica, Universita` degli Studi “Magna Graecia” di Catanzaro, Catanzaro, 2Dipartimento
di Biologia e Patologia Cellulare e Molecolare “L. Califano”, Universita` degli Studi di Napoli “Federico II”, Istituto di Endocrinologia
ed Oncologia Sperimentale “G. Salvatore” of the Consiglio Nazionale delle Ricerche, and 3Dipartimento di Chimica Biologica,
Universita` degli Studi di Napoli “Federico II”, Napoli, Italy
In this review we have summarized the more recent studies on the expression of mammalian galectins. One interesting
observation that can be made is that in most of microarrays and/or differential display analysis performed in recent years
one or more galectins have been picked up. From a critical evaluation of the pertinent studies the main conclusion that can
be drawn is that, although it is not yet clear whether the 14 galectins identified so far have functions in common, a striking
common feature of all galectins is the strong modulation of their expression during development, differentiation stages
and under different physiological or pathological conditions. This suggests that the expression of different galectins is
finely tuned and possibly coordinated. In spite of these observations it is rather unexpected that very few studies have
been performed on the molecular mechanisms governing the activity of galectin genes.
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Introduction
Galectins belong to a family of proteins, which contain one
or more carbohydrate recognition domains (CRD) with affin-
ity for β-galactosides [1–3]. Another common characteristic of
galectins is their cytosolic localization and their ability to be
secreted from the cytosol by non-classical pathways or to be
translocated to the nucleus or to other cellular compartments.
All galectins lack a typical signal peptide. These proteins are
evolutionary conserved from fungi to man. To date fourteen
galectins have been identified in mammals [3,4]. According to
their structural organization [5,6] mammalian galectins can be
subdivided in three groups: prototype, consisting of a peptide
chain containing a single CRD and found either as monomers
(galectins-5, -7, -8, -10, -13 and -14) or as monomers/dimers
(galectins-1, -2 and -11); tandem repeat, characterized by the
presence of two CRD on the same chain connected by a short
link peptide (galectins-4, -6, -8, -9 and -12); and chimera, com-
posed of a single CRD attached to a domain possessing different
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functions (galectin-3). There are six known galectin-8 isoforms,
of which three belong to the prototype group and three to the
tandem repeat group [7].
The function of galectins in the extracellular compartment
has been thoroughly investigated; they may modulate cell-cell
and cell-matrix interactions, cell adhesion and cell signaling
by cross-linking to glycoconjugates that contain β-galactosides
[1–3,8]. Each member of the galectin family possesses addi-
tional specific functions. Galectins-1 and -3 have been tradi-
tionally involved in the process of carcinogenesis, tumor pro-
gression and metastatic potential [9,10]. Recently, galectin-1
has been identified as a selective binding partner of oncogenic
H-Ras (12V) and mediates membrane anchorage of this onco-
gene and cell transformation [11,12]. The mechanisms through
which galectin-3 favors the metastatic process have been further
investigated and several other galectins have been associated to
tumor progression [13,14]. Some galectins do play an impor-
tant role as pro-apoptotic or anti-apoptotic factors in normal
and tumor cells and in cells of the immune system [15–25].
Recent studies have established a role of galectins-1 and -3,
in T cell homeostasis and survival and in T cell-mediated im-
mune disorders; of galectins-9, -10 and -14 in the context of
allergic processes [4,17,26–28]; of galectins-1 and -3 in acute
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inflammation and in microbial infections [27]. Some galectins
do participate in the development and differentiation programs
[29]. For instance, high galectin-1 expression has been detected
in sensory, motor and olfactory neurons and it has been demon-
strated to participate in the regulation of olfactory axon fascicu-
lation and targeting [30,31]; galectin-1 also regulates myoblast
and fibroblast differentiation [32]. Galectin-7 might play a role
in the modulation of the proliferation/differentiation program
of epithelia [33,34]. Galectins-1, -3 and -5 are expressed in
the trophoectoderm, but a putative role in embryonic implanta-
tion has not been confirmed by the analysis of knock-out mice
[35]. Additional intracellular functions of galectins-1 and -3
include pre-mRNA splicing [36,37]. Galectin-9 in addition to
its other function as an eosinophil chemoattractant (ecalectin)
[26] has been identified as the urate transporter/channel [38] a
transmembrane protein. The finding that galectin-9 gene gives
rise to different mRNA isoforms sustain the idea of the involve-
ment of galectin-9 both in immune/inflammation processes and
in potential-sensitive uric acid translocation [39]. Galectin-10
has been identified as the Charcot-Leiden crystal protein of
eosinophils and basophils [40].
Because most if not all galectins are functionally multivalent
exerting their wide range of biological activities both during
development and in adult tissues, it is clear that each galectin
must have a specific role, either intra- or extracellularly, de-
pending on the tissue context or on a given differentiation or
developmental stage. In other words each galectin should act in
a given tissue at a given time. Hence, a precise modulation of
their expression and activity is required. Such modulation can
be exerted mainly at the transcriptional level or by changing the
subcellular localization or, possibly, by the modulation of the
expression or glycosilation of specific ligands.
Tissue distribution of galectins
The expression pattern of galectins varies among different adult
tissues, changes during development and it is dramatically al-
tered upon neoplastic transformation or in other pathological
conditions. Most of these data are summarized in Table 1.
Galectin-1, -3, -8 and in part -5 and -9 are expressed in a wide
range of tissues. The analysis of galectin-5 and -9 distribution
was first complicated by the high degree of similarity. The only
certain location for galectin-5 is in rat reticulocytes, and their
precursors. Using more specific probes, galectin-9 was found
especially in thymus, liver, intestine, spleen, and, at lower lev-
els, in reticulocytes [41,42]. The expression of galectin-9 is
also developmentally regulated and is detected at high levels in
developing thymus and liver [42].
The expression pattern of the remaining galectins is much
more restricted (Table 1). As an example of restricted expres-
sion related to a specific function, galectin-14 expression in
eosinophils appears to have an important role in allergic in-
flammation [28]. Another galectin expressed in a specific or-
gan, the lens, is GRIFIN (galectin-related inter-fiber protein)
[43] or galectin-11 [4].
Most galectins are also expressed during embryogenesis [29].
The spatiotemporal distribution of galectin-1 and -3 in human
and mouse embryogenesis has been thoroughly investigated
[29]. Galectin-1 and -3 are first expressed in the trophoecto-
derm cells of the implanting embryo and have been implicated
in the process of implantation [29]. In mouse embryo a promi-
nent expression of galectin-1 in the myotomes of the somites
and a specific detection of galectin-3 in the notochord, carti-
lage and skin has been reported [29]. In human embryogenesis
galectin-1 is found prevalently in connective tissues and some
epithelia such as the basal layers of the skin and epithelial cells
of the gonads whereas galectin-3 is detected mainly in epithelia
but also in preossifying condrocytes, notochord, liver and my-
ocardial cells. Because the expression of cell surface lactosam-
minoglycans undergoes stage- and tissue-specific changes dur-
ing embryogenesis, it is possible that galectins participate to
the complex process of tissue differentiation.
Modulation of galectins expression
Although it is not yet clear whether the 14 galectins identi-
fied so far have functions in common, a striking feature of all
galectins is the strong modulation of their expression during
development, differentiation stages and under different physio-
logical or pathological conditions. The best studied conditions
in which galectins expression is modulated are presented in
Table 1. However, it is expected that much more information
will be available in a short time considering the number of
studies currently in progress.
Waiting for further elucidation of the physiological activities
of galectins, one of the most exciting fields in the galectin re-
search is the potential biomedical use of galectins or galectin
inhibitors as diagnostic tools or therapeutic agents in neoplastic
and autoimmune diseases. Carbohydrate structures have been
for a long time implicated in cell adhesion, immunomodulation
and cancer cell invasion and metastasis, but only in the past
few years many investigators have focused attention on the en-
dogenous molecules that bind carbohydrates, i.e. galectins. Be-
cause galectins are involved in the modulation of cell adhesion,
cell growth, immune response, apoptosis and angiogenesis, it
is clear that changes of their expression might have a critical
role in tumor progression.
In the last decade the role and expression pattern of galectin-1
and -3 in carcinogenesis and tumor progression have been ex-
tensively investigated [9,10]. In more recent years it has been
found that the expression of other galectins also changes in tu-
mors (Table 1). A particularly attractive system for this kind
of studies has been thyroid carcinogenesis. Galectin-1 expres-
sion correlates with the degree of malignancy in rat thyroid cell
lines transformed with several cellular or viral oncogenes [44].
Galectin-1 mRNA levels increase 20-fold in low tumorigenic
and up to 100-fold in high tumorigenic cells. Galectin-1 mRNA
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Table 1. Distribution of galectins and relevant changes of expression in different conditions
Regulation in systems
Galectin Prevalent distribution Up-regulation Down-regulation Regulators
1 Most tissues: Most transformed cell Tumors: head and Azacytidine,
skeletal lines and tumors. Chronic neck butyrate, RA,
muscle, heart, pancreatitis. Parasites budesonide,





3 Macrophages, Tumors: thyroid, colon Tumors: colon RA, Heat-shock,
epithelia late stages, gastric, CNS, initial stages, trypsine (down).
bladder, large cell breast, ovarian, alkylating agents,
lymphomas. Renal failure, prostate, head and UV-C, HIV tat
chronic pancreatitis, brain neck, basal cell. (up)
ischemia. Streptococcal HTLV-I infection
pneumonia







7 Epithelia Tumors: breast Tumors: bladder, RA (down).
skin UV-B (up)




9 (ecalectin) Eosinophils, Hodgkin’s lymphomas. Tumors: melanoma





9 (urate Kidney, Hodgkin’s Tumors:





10 Eosinophils, Butyrate (up)
basophils
11 (GRIFIN) Lens





14 Eosinophils Allergic response
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levels are very low in normal thyroid, non-neoplastic goiters,
adenomas and follicular carcinomas, while are increased (5-20-
fold) in a large proportion of papillary and in almost all the ag-
gressive anaplastic carcinoma [45]. By immunohistochemical
studies, however, a higher galectin-1 content compared to nor-
mal thyroid (20-30-fold) has been reported in all follicular and
also in some medullary carcinomas [46]. In these latter studies
the percentage of papillary carcinomas positive for galectin-
1 was higher than in Northern blot studies. The expression of
galectin-3 in thyroid tumors shows a very similar behavior being
very low or absent in non-malignant and high in all malignant
tissue samples [46–48]. Thus, galectin-1 and -3 are potentially
very useful diagnostic markers in the thyroid neoplastic pathol-
ogy. Galectin-3 evaluation in thyroid specimens obtained by
fine-needle aspiration biopsy can distinguish, in a pre-surgical
phase, follicular, papillary and follicular variant of papillary car-
cinomas from the benign follicular adenomas allowing a better
selection of the patients that really require surgery [48,49].
It is worth to draw the attention to the fact that specific
galectins are modulated in different tumors and that in the same
kind of tumor different galectins are up or down modulated
(Table 1). An attractive system to illustrate this last point is
colorectal cancer in which galectin-1 is upregulated, galectin-4
and -8 are downregulated and galectin-3 is downregulated in
the initial stages and upregulated during tumor progression and
metastasis [50–53].
Galectin expression is modulated in other pathological con-
ditions such as immune response, inflammation and infection
in which each galectin may play a specific role [4]. All these
observations support the possible use of galectins or galectin
inhibitors in therapy as immunosuppressors or as antimetastatic
agents, respectively. Very interestingly, saccharides interacting
with galectins inhibit metastasis of experimental cancer in vivo
[14,54]. The biomedical use of galectin-1 inhibitors is particu-
larly attractive since the galectin-1 and galectin-3 null mutant
mice are relatively healthy [29].
In addition to changes under physiopathological conditions,
galectins expression can be modulated by a variety of physic-
ochemical agents (Table 1). For example, a transient increase
in galectin-1 expression is achieved upon treatment of thyroid
cells with the thyroid stimulating hormone (TSH) [55]. Treat-
ment of oncogene transformed neural cells with retinoic acid
(RA), a differentiating agent, leads to extinction of galectin-1
expression [55]. Conversely, it has been reported that in human
head and neck carcinoma cells, galectin-1 expression is stimu-
lated by sodium butyrate (butyrate) treatment [56]. Because
galectin-1 expression is increased also upon treatment with
other inhibitors of histone deacetylases, it has been proposed
that galectin-1 expression be linked to the status of histone
acetylation [56]. In human endothelial cells galectin-1 synthesis
is upregulated by minimally oxidized low-density lipoprotein
(MM-LDL) [15,57]. Activation of galectin-1 gene can be also
achieved by fusing non-expressing cells with tumor cells or by
treatment of non-expressing cells with the DNA demethylat-
ing agent azacytidine [58–60]. Galectin-3 expression is mod-
ulated in cultured cells by differentiation inducers [61], is in-
duced by human T lymphotropic virus-I infection of human
T lymphocytes [62], and by the HIV tat protein [63]. Finally,
galectin-7 expression in keratinocytes is moderately repressed
by RA, a behavior contrasting with other keratinocyte markers
[33,64].
Transcriptional regulation of galectin genes
The gene structure and chromosomal localization of the avail-
able human galectin genes has been determined (Table 2) using
the MapViewer program and Entrez genome database at the
NCBI web site.
Based on what has been discussed in the previous paragraphs,
the study of the transcriptional regulation of galectin genes is
particularly worth of interest. Despite these considerations, in
recent years still very few experimental data have appeared
on this subject. The upstream regulatory regions of galectin-
1, -2, -3, -4, -6 and -10 from different species [41,52,65–70],
and more recently human galectin-9 and -12 [24,38] and rat
galectin-11 (GRIFIN) [43] have been cloned. Only for few of
them promoter function studies have been performed. The main
functionally characterized or suggested as potential regulatory
elements within the galectin genes are shown in Figure 1.
A small genomic region spanning the transcription start site
(−63/+45) is sufficient for the transcriptional activity of the
mouse galectin-1 gene [68]. Both an upstream and a down-
stream position-dependent cis-elements are necessary for effi-
cient transcriptional activity [68]. Recently, an additional start
site has been mapped at position−31. A Sp1 site (−57/−48) and
a consensus initiator (Inr) element, which partially overlaps a
non-canonical TATA box, direct RNA initiation from both start
sites [71]. The upstream transcripts contribute to more than half
of the galectin-1 mRNA population. The 5′ end of this transcript
is extremely GC-rich and may fold into a stable hairpin struc-
ture, which could influence translation [71]. Lotan et al. have
Table 2. Chromosomal location and structure of human genes
encoding galectins
Human No. of Transcript
Gene (Protein encoded) locus exons length (kb)
LGALS1 (galectin-1) 22q12 4 0.6
LGALS2 (galectin-2) 22q12 4 0.5
LGALS3 (galectin-3) 14q21-22 6 1.1
LGALS4 (galectin-4) 19q13.2 9 1.0
LGALS7 (galectin-7) 19q13.2 4 0.6
LGALS8 (galectin-8) 1q42-q43 11 4.3
LGALS9 (galectin-9) 17q11.1 11 1.7
CLC (galectin-10) 19q13.1 4 0.7
LGALS12 (galectin-12) 11q13 9 1.7
PP13 (galectin-13) 19q13.1 5 0.6


















































Figure 1. Promoter regions of some galectin genes. The approximate position of the putative and/or characterized regulatory
element is indicated: Sp1, CAAT box, TATA box, C/EBP, nuclear factor kB binding site (NFkB), cAMP responsive element (CRE), sis
inducible element (SIE), consensus binding site for p53 (p53), E box (E), intestine specific sequence (IS), myeloid specific sequence
(MS), GATA factor binding site (GATA), purine rich sequence 1 (PU.1), AML binding site (AML), eosinophil transcription factor binding
site (EoTF), sodium butyrate (butyrate) and retinoic acid (RA) responsive sequences, initiator (Inr), AP2 and AP1. For further details
see text. Bent arrows indicate the transcription start sites. The second intron of the galectin-3 gene, 651 bp long, is not drawn to
scale.
shown that the Sp1 site is also crucial for the butyrate-induced
expression of galectin-1 while an RA responsive region was
mapped within the region −1578/−1448 [70,72].
A few regulatory elements have been recognized in the
LGALS2 gene promoter region [65]. Among them an AML
recognition site similar to that found in the CLC gene pro-
moter has been identified (Figure 1). Because AMLfactors have
been suggested to be master regulators of hematopoiesis [73],
their role in the regulation of LGALS2 gene, which has a re-
stricted expression in the gastrointestinal tract, remains to be
established.
The human and mouse galectin-3 promoters have been func-
tionally characterized [69]. The genomic region from −339 to
+141 has promoter activity. Galectin-3 gene can be consid-
ered an early immediate gene since its expression is rapidly
increased upon serum stimulation. The serum responsive acti-
vation regions are located between−513 and−339 and between
−339 and −229. However these regions lack a typical sequence
motif, which forms the core-binding site of the serum response
element. The authors suggest that serum activation may be ac-
complished via different elements such as SIE (sis-inducible
elements) or CRE that are present in the galectin-3 promoter
(Figure 1). Legrand et al. have demonstrated that the second
intron of the galectin-3 gene has promoter activity, which is
downmodulated by wild-type p53 but not by a mutated form
of p53 [67] (Figure 1). The distal and the internal promoters
are independent rather than exclusive. It has been shown that
transcripts from the internal promoter define an internal gene
embedded within LGALS3 and named GALIG (galectin-3 in-
ternal gene). GALIG transcripts contain two overlapping open
reading frames, which, upon translation, give rise to proteins
unrelated to galectin-3 and localized to different subcellular
compartments [74]. By BLAST analysis we could not identify
transcripts homologous to GALIG in other species. The rabbit
galectin-3 gene has been isolated and characterized. Its struc-
ture has an organization similar to that of the murine galectin-3
gene. The genomic sequences located upstream from its 5′ end,
upon insertion upstream from a promoter-free reporter gene,
exhibit a strong promoter activity. This activity is upregulated
upon treatment of transfected smooth muscle cells with phor-
bol 12-myristate 13-acetate (PMA) as well as upon transfection
with an EJ/ras encoding plasmid. Conversely, it is downmodu-
lated upon transfection with wild-type p53 but not with mutated
p53. The regulatory sequences involved in the positive regula-
tion of the gene were located upon serial deletion experiments
[75].
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The mouse Lgals6 gene promoter contains a sequence be-
tween bp −354 through bp −367, which is highly homologous
to a 19 bp sequence within the apolipoprotein B upstream re-
gion that has been implicated in intestine-specific expression of
this protein [76]. In addition the galectin-6 promoter contains
several E boxes, DNA elements that have been implicated in
the regulation of gene expression in proliferating and differen-
tiating epithelial cells. In particular, in the galectin-6 promoter
region, one E box resembles the MycMax binding site and oth-
ers resemble the MyoD binding site [76].
Human galectin-10 promoter constructs have been function-
ally analyzed in the attempt to identify DNA elements that reg-
ulate gene expression during the commitment and differentia-
tion of the eosinophil lineage [66]. The authors found that the
−292 to −411 bp region of the galectin-10 promoter may con-
fer some specificity for expression in the eosinophil lineage.
The galectin-10 promoter contains two consensus GATA bind-
ing sites, a purine-rich sequence that presents potential bind-
ing sites for PU.1, a member of the ets family of genes, as
well as sequences described in other myeloid-specific genes
[66] (Figure 1). In a recent paper Dyer and Rosenberg have
performed a functional study of the human galectin-10 pro-
moter [77]. The integrity of the Sp1 site, of the Oct site and
of the GATA and EoTF sites (Figure 1) is necessary for full
promoter activity. The Sp1 and Oct factors bind the respec-
tive sites in in vitro assays. Similarly to galectin-1, galectin-10
expression is induced by butyrate and this effect requires the
integrity of the Sp1 site. Moreover, AML3 and YY1 factors can
bind their respective sites (AML and Inr) and repress promoter
function.
The rat galectin-11 (GRIFIN) promoter region contains three
sets of direct repeats [43]. Within or between these repeats sev-
eral consensus sequences for C-myb and δEF1 have been iden-
tified [43] (Figure 1). The presence of several δEF1 sites in the
promoter region and in exon 4 suggests a role in the lens specific
expression of this gene. In fact, a similar distribution of binding
sites for the zinc finger δEF1 transcription factor is found within
the δ1-crystallin chicken gene, whose lens-specific expression
has been shown to depend on this factor [43].
In the human galectin-12 promoter region, in addition to
several Sp1 and AP2 sites, a potential binding site for the
CCAAT/enhancer-binding protein (C/EBP) has been identified
[24] (Figure 1). This suggests a role of adipose-specific en-
hancers such as C/EBP on galectin-12 induced expression and
apoptotic potential.
Role of DNA methylation in the control of galectin genes
expression
It is becoming evident that epigenetic changes are among the
most common alterations observed in human cancer cells. The
expression of several oncogenes and tumor suppressor genes is
profoundly altered through changes in their methylation pattern
in human tumors of different origins [78,79]. Because several
galectins are strongly modulated and play a role in the neo-
plastic process, the study of DNA methylation in the control
of galectin genes is particularly worth of interest. For several
years we have studied the regulation of the galectin-1 gene ex-
pression. The expression of this gene is increased in oncogene
transformed cell lines [44] and in a variety of human tumors
[45,80]. These studies led us to identify the methylation status
of the galectin-1 promoter as the main mechanism that con-
trols the expression of the gene in transformed cells, in normal
tissues and in tumors. The demethylating agent azacytidine is
able to reactivate galectin-1 transcription in several cell systems
[58–60,81]. Trans-acting factors that potentially could activate
galectin-1 gene are produced by both normal and transformed
cells [68] but in several cell hybrids obtained by the fusion of
human osteosarcoma cells with normal rat liver cells, a con-
stant reactivation of the previously silent galectin-1 alleles was
observed [58]. We have established that the mechanism con-
trolling the activation of galectin-1 gene in tumors and in cell
hybrids is the transition from a methylated to an unmethylated
state of 11 CpG sites lying in a small 90 bp region surrounding
the transcription initiation site [81] (Figure 1). On the contrary,
in the adjacent region no changes in the methylation profile
were observed. Bisulfite genomic sequencing of the galectin-1
promoter in normal tissues showed that the methylation pattern
in each cell was heterogeneous but some features were always
conserved: (i) the density rather than site-specific methylation
is responsible of the activity of the gene; (ii) a specific site (the
last of the 11 CpG cluster) is always methylated in both nor-
mal expressing and nonexpressing tissues, in all cells and on
both strands [10,82]. On these evidences we have developed
a model in which specific CpG sites in their methylated state
could be part of an in-cis signal for the recruitment of ubiqui-
tous regulatory molecules (methylases, demethylase, methyl-
binding proteins). Interestingly, we have found that what dis-
tinguishes the active alleles of a normal expressing tissue from
that of a tumor is the loss of methylation of the specific site
that is always methylated in normal expressing and nonex-
pressing tissues (L. Chiariotti, and C.B. Bruni, unpublished
results).
To date there are no data on the role of DNA methylation in
the control of expression of other galectin genes. In Figure 2
we present the distribution of CpG sites within the genomic
region surrounding the transcription start site of the available
human galectin genes. It is interesting to observe that most of
the galectin genes that are strongly modulated in carcinogene-
sis exhibit a distribution of CpG sites around the transcription
initiation site compatible with a role of DNA methylation in
transcription control.
In conclusion, the identification of coordinate mechanisms
governing the activity of the different galectin genes and the
search for common biological activities of their products has
been elusive so far. It is hoped that a growing number of studies
in these two apparently unrelated fields could lead to a unifying
picture of the biological functions of this family of proteins.












Figure 2. Distribution of CpG dinucleotides in the human galectin genes −1000/+1000 regions. Vertical lines indicate the position
of each dinucleotide in the DNA sequences of the indicated human galectin genes. Sequences were retrieved using the MapViewer
program and Entrez genome database at the NCBI web site and analyzed using the GeneWorks program produced by IntelliGenetics
Inc.
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